盐酸吉西Gemcitabine市场规模、份额及成长分析（按类型、应用、分销管道和地区）- 产业预测，2025 年至 2032 年

预计 2023 年全球盐酸Gemcitabine市场规模将达到 22 亿美元，从 2024 年的 23.3 亿美元成长到 2032 年的 36.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.7%。

全球盐酸吉西Gemcitabine市场受到癌症发生率大幅上升的推动，尤其是胰臟癌、卵巢、肺癌和乳癌。盐酸吉西Gemcitabine已成为癌症治疗的重要组成部分，是各种固体癌化疗方案的关键组成部分。人口老化、生活方式改变和环境风险等因素导致癌症发生率上升和对有效治疗方法的需求增加。在新兴国家，诊断率、医疗保健可近性和化疗利用率的提高进一步推动了市场成长。药物製剂、脂质体递送系统和联合治疗的技术创新正在提高医生的使用率和患者的合格。专利后学名药的兴起正在扩大患者的用药管道，而医疗保健支出的增加和向个人化肿瘤治疗的转变预计将维持各地区的市场扩张。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

盐酸吉西Gemcitabine市场规模（按类型）及复合年增长率（2025-2032）

• 市场概览
• 原厂产品
• Gemcitabine盐酸吉西非专利

盐酸吉西Gemcitabine市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 胰臟癌
• 非小细胞肺癌
• 乳癌
• 其他的

盐酸Gemcitabine市场规模（依通路划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局

盐酸吉西Gemcitabine市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Eli Lilly and Company（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Pfizer Inc.（USA）
• Mylan NV（USA）
• Fresenius Kabi AG（Germany）
• Accord Healthcare（United Kingdom）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories（India）
• Cipla Ltd.（India）
• Aurobindo Pharma（India）
• Sandoz International GmbH（Germany）

结论和建议

Global Gemcitabine Hydrochloride Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.33 billion in 2024 to USD 3.62 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global market for Gemcitabine Hydrochloride is being driven by a significant increase in cancer incidence, particularly in pancreatic, ovarian, lung, and breast cancers. As a vital component of chemotherapy regimens for various solid tumors, Gemcitabine Hydrochloride has become essential in oncology treatment. Factors like aging populations, lifestyle changes, and environmental risks contribute to rising cancer rates and demand for effective therapies. Emerging economies are witnessing improved diagnosis rates, healthcare access, and chemotherapy utilization, further promoting market growth. Innovations in drug formulations, liposomal delivery systems, and combination therapies are enhancing both physician use and patient eligibility. The advent of generics post-patent expirations has broadened patient access, while escalating healthcare expenditures and a shift towards personalized oncology are set to sustain market expansion across regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gemcitabine Hydrochloride market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gemcitabine Hydrochloride Market Segments Analysis

Global Gemcitabine Hydrochloride Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into Branded and Generic. Based on Application, the market is segmented into Pancreatic Cancer, Non-Small Cell Lung Cancer, Breast Cancer and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gemcitabine Hydrochloride Market

The increasing prevalence of cancer worldwide, particularly in cases such as pancreatic, lung, breast, and bladder cancers, significantly fuels the growth of the gemcitabine hydrochloride market. Its extensive efficacy and favorable safety profile have established gemcitabine hydrochloride as a fundamental component in cancer treatment regimens. Additionally, the ongoing research into new applications and the exploration of combination therapies involving gemcitabine further enhances its demand. As healthcare providers seek effective treatment solutions, the robust clinical interest surrounding this drug will likely contribute to sustained market progression, highlighting its vital role in oncology pharmacotherapy.

Restraints in the Global Gemcitabine Hydrochloride Market

The global market for gemcitabine hydrochloride faces significant constraints due to the expiration of patents on branded formulations, which has resulted in a surge of generic alternatives. This influx has intensified price competition, leading to reduced profitability for original manufacturers as they grapple with decreasing prices. While the availability of more competing products enhances accessibility for patients, it simultaneously places financial pressure on companies, potentially stifling innovation and investment in the development of new indications or improved delivery methods. As a result, these factors may hinder the growth and penetration of the gemcitabine hydrochloride market on a global scale.

Market Trends of the Global Gemcitabine Hydrochloride Market

The Global Gemcitabine Hydrochloride market is witnessing a significant trend towards the adoption of Artificial Intelligence (AI) in personalized chemotherapy. Key players are leveraging advanced AI and data analytics to enhance treatment planning, focusing on real-time patient monitoring and predictive modeling. This innovative approach aims to optimize individualized dosing plans, ensuring a more accurate and effective delivery of cancer treatment. As healthcare providers increasingly recognize the potential of AI to improve patient outcomes, the integration of these technologies in Gemcitabine Hydrochloride therapies is expected to drive market growth, transforming how cancer treatments are tailored to meet specific patient needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Gemcitabine Hydrochloride Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generic Gemcitabine Hydrochloride

Global Gemcitabine Hydrochloride Market Size by Application & CAGR (2025-2032)

• Market Overview
• Pancreatic Cancer
• Non-Small Cell Lung Cancer
• Breast Cancer
• Others

Global Gemcitabine Hydrochloride Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gemcitabine Hydrochloride Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations